TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02559973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBP-6000
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE Sublingual Film
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBOXONE Sublingual Film
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE Sublingual Film
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
Study: NCT02916069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nearinfrared Spectroscopy (NIRS)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler (TCD)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
Study: NCT04650230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices
Study: NCT00709150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management
Description: Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
Study: NCT02473471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
Study: NCT00432913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic Acid (EPA)
Description: Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: At baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: At baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: At baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical chemistry
Description: Full blood count at baseline, month 3 and month 6.
Study: NCT00977860

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: 36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
Study: NCT00149162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: proleukin
Description: One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months
Study: NCT02895230

Intervention type: OTHER
Intervention: Standard care
Description: An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
Study: NCT01698372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena device (Group A)
Description: This portable device is applied to initiate negative pressure therapy to a wound site.
Study: NCT04003012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Study: NCT00742924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT04003012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%
Study: NCT00742924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02129998

Intervention type: OTHER
Intervention: IVF/ICSI treatment
Study: NCT01906398

Intervention type: OTHER
Group type: OTHER
Intervention: ketogenic diet
Description: KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
Study: NCT04353271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
Study: NCT00224445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg capsule administered orally QD
Study: NCT03159273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice Group
Description: Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
Study: NCT04048382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
Study: NCT01576666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT03387891

Intervention type: DEVICE
Intervention: Cortrium C3 device
Description: Paired measurements of data from C3 device with golden standard methods or equipment
Study: NCT00943254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Tech Education
Description: Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Tech Education
Description: Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
Study: NCT05466981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Counseling
Description: The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
Study: NCT01350713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone iodine
Description: one local application of 10% povidone iodine ointment
Study: NCT00742924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT01350713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone iodine
Description: one local application of 10% povidone iodine ointment
Study: NCT02490943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress Before Injection
Description: Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Compress After Injection
Description: Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
Study: NCT03745638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Study: NCT01186003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
Study: NCT03600493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
Study: NCT03420313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone sublingual tablets
Description: 24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
Study: NCT03867110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 mg
Study: NCT00742924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT03745638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT02795299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gerilimzumab
Description: Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gerilimzumab
Description: Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gerilimzumab
Description: Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
Study: NCT01726543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty and phacoemulsification
Description: As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-penetrating deep sclerectomy and phacoemulsification
Description: A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
Study: NCT01569815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400 mg once daily
Study: NCT02512445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Guilt Reduction Therapy
Description: Trauma focused therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care Therapy
Description: Supportive therapy